SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma’s arm to acquire 100% membership interest in Lannett Company LLC

31 Jul 2025 Evaluate

Aurobindo Pharma’s wholly owned subsidiary -- Aurobindo Pharma USA Inc has entered into a definitive agreement with Lannett Seller Holdco, Inc under which Aurobindo Pharma USA Inc will acquire 100% of membership interest in Lannett Company LLC from Lannett Seller Holdco, Inc.

The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities. Through this acquisition, Aurobindo will gain access to a complementary portfolio of profitable products, growing Contract Development and Manufacturing Organization (CDMO) business and U.S.-based manufacturing facility with significant excess capacity (425k sq ft facility with around 3.6 billion doses capacity) and with potential for further expansion.

The acquired product portfolio is primarily focused on non-opioid controlled substances, particularly in ADHD therapeutics for which Aurobindo currently has a limited presence. This acquisition strengthens Aurobindo’s ability to serve the U.S. generics space and provides strategic diversification into a specialized, high-value therapeutic category.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma Share Price

1367.70 -17.95 (-1.30%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×